Press Releases

American Biogenetic Sciences Appoints Dr. Yale Arkel Coordinator of Clinical Development

Leading Hematologist to Spearhead Ongoing Development of Vascular Diagnostic Program

COPIAGUE, N.Y., Jan. 21 -- American Biogenetic Sciences, Inc. (ABS) (Nasdaq: MABXA - news) has announced the appointment of Yale Arkel, M.D., FRCP as the company's Coordinator of Clinical Development for its vascular diagnostic products. Dr. Arkel, who is Director of the Blood Disorder Center for Hemostasis and Thrombosis at Overlook Hospital in Summit, New Jersey, will maintain his current clinical and research duties, and will act as an outside consultant to the company.

``This is an important and timely step for ABS as we move to establish our Thrombus Precursor Protein (TpP) diagnostic test in the clinical setting,'' said John S. North, President and CEO. ``Dr. Arkel is an experienced and respected hematologist in the field of hemostasis. He brings precisely the expertise ABS needs to guide the ongoing clinical development of, and help broaden demand for, our vascular diagnostic products. We are delighted that Dr. Arkel has agreed to act in this capacity ''

``I am both honored and pleased to be expanding my involvement with ABS,'' said Dr. Arkel, who has served as principal investigator on several clinical trials sponsored by ABS. ``I am particularly eager to participate in efforts to further the use of the TpP test, as a standard practice in the early diagnosis and prevention of life-threatening blood clots.''

Trials Underway to Demonstrate TpP's Potential to Save Lives, Reduce Health Costs As Coordinator of Clinical Development, one of Dr. Arkel's chief tasks will be to gather additional data, and design new post-marketing collaborative clinical trials for TpP in both its microtiter and point of care format. ``I believe that ongoing clinical trials, some of which are nearing completion, will further validate previous studies showing that TpP is the most accurate and flexible test available for vascular conditions. Given the estimated 55 million patients in the U.S. alone with thrombotic disorders, I believe that increased use of TpP will save lives and greatly reduce hospital costs.''

Dr. Arkel is a highly respected clinician and investigator in hematology. He was one of the founders and first president of the North American Specialized Coagulation Laboratories Association, and is a long standing member of the American Society of Hematology and the International Society on Thrombosis and Hemostasis. In addition to his duties at the Overlook Hospital, Dr Arkel is an Associate Professor of Clinical Medicine at the College of Physicians and Surgeons of Columbia University in New York. Dr. Arkel received his B.A. from New York University, his M.D. from Chicago Medical School, and his hematology training at Montefiore Medical Center, New York City. Dr. Arkel directed the first comprehensive hemophilia diagnostic and treatment center in New Jersey.

American Biogenetic Sciences, based in Copiague, New York, researches and develops diagnostic tests for cardiac conditions and infectious diseases, as well as new treatments for neurological conditions including epilepsy, migraine, mania, Parkinson's and Alzheimer's disease. ABS also seeks out new technologies and conducts research and development throughout its Global Scientific Network in the U.S., Europe, Israel, Russia and China.

Statements in this release that are not strictly historical are ``forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995, and should be considered as subject to various risks and uncertainties that could cause actual results to differ materially from those anticipated. For further details and a discussion of these risks and uncertainties, see the Company's Securities and Exchange Commission filings, including its Annual Report or Form 10-K.